Close Menu

NEW YORK – Adaptive Biotechnologies and GlaxoSmithKline announced late Tuesday a collaboration to use Adaptive's ClonoSeq assay to assess minimal residual disease (MRD) across GSK's portfolio of hematology products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.